Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026

Company outlines development priorities and upcoming milestones for biologics and small-molecule programs targeting atopic dermatitis and other inflammatory conditions.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Aclaris Therapeutics (NASDAQ:ACRS) detailed its strategy and upcoming clinical milestones for a TSLP-targeted antibody platform and an ITK-focused kinase inhibition franchise during a recent investor presentation. The company expects multiple readouts in the back half of 2026, including results from a Phase II study of its TSLP monoclonal antibody in moderate-to-severe atopic dermatitis, as well as data from early-stage trials of a bispecific TSLP/IL-4R antibody and an oral ITK inhibitor.

Why it matters

Aclaris’ pipeline reflects the company’s focus on developing novel therapies for chronic inflammatory skin conditions and rare disorders. The TSLP and ITK programs represent potential best-in-class approaches that could address significant unmet needs in atopic dermatitis and other immune-mediated diseases.

The details

On the biologics side, Aclaris is advancing a TSLP monoclonal antibody in a 90-patient Phase II study in moderate-to-severe atopic dermatitis, with results expected in late 2026. The company is also developing a bispecific antibody that combines the TSLP antibody with an IL-4 receptor construct, designed to improve half-life compared to the TSLP antibody alone. For the oral small-molecule franchise, Aclaris is progressing ATI-2138, a covalent ITK inhibitor that also targets JAK3. In an open-label study, ATI-2138 demonstrated reductions in EASI and pruritus scores in patients with moderate-to-severe atopic dermatitis. The company is now engineering newer ITK-selective compounds to support once-daily dosing.

  • Aclaris expects to report results from the Phase II study of its TSLP monoclonal antibody in late 2026.
  • Additional data from the single-ascending dose study of the TSLP/IL-4R bispecific antibody are expected in the coming months.

The players

Aclaris Therapeutics

A clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for dermatologic diseases and related rare disorders.

Neal Walker

Chief Executive Officer and Board Chair of Aclaris Therapeutics.

Hugh Davis

President and CEO of Aclaris Therapeutics.

Roland Kolbeck

Chief Scientific Officer of Aclaris Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Aclaris’ pipeline of TSLP-targeted biologics and ITK-focused small molecules represents a promising approach to addressing chronic inflammatory skin conditions and rare disorders. The company’s focus on developing potentially best-in-class therapies could position it to make meaningful advances in an increasingly competitive landscape.